Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
Big Money Move: Investment Manager Buys $6.9 Million Worth of Johnson & Johnson Shares, According to Recent Filing
06:47pm, Monday, 13'th Oct 2025
Cyndeo Wealth Partners, LLC purchased 40,238 shares of Johnson & Johnson (JNJ 0.09%) for an estimated $6.89 million during the quarter ended September 30, 2025, according to its October 10, 2025 SEC f
Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch
12:27pm, Monday, 13'th Oct 2025
Health care giant Johnson & Johnson (NYSE:JNJ) has had a good year with its shares trading near all-time highs. The company looks to keep a trend of beating analyst estimates when third-quarter financ
Is J&J's MedTech Segment Set for Another Quarter of Growth?
09:21am, Monday, 13'th Oct 2025
J&J's MedTech sales are gaining traction in Cardiovascular, Surgery, and Vision, even as China???s VBP program continues to weigh on growth.
Douglas Lane Adds $6 Million in J&J Stock Ahead of Earnings and Possible Biotech Deal
03:14pm, Sunday, 12'th Oct 2025
Douglas Lane & Associates, LLC disclosed a purchase of 34,948 shares of Johnson & Johnson (JNJ -0.24%) in an SEC filing on Friday, representing an estimated $6 million transaction based on average pri
Johnson & Johnson To Acquire Protagonist? It'd Be A Good Deal To Make
09:00am, Sunday, 12'th Oct 2025
Johnson & Johnson (JNJ) is rumored to be in talks to acquire Protagonist Therapeutics (PTGX), following significant buyout speculation and a 30% PTGX stock surge. PTGX's value is underpinned by its or
Wall Street Week Ahead
06:57am, Sunday, 12'th Oct 2025
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
3 Defensive Stocks to Watch as Trade Tensions Resurface: GILD, JNJ, KR
10:11pm, Friday, 10'th Oct 2025
Resurfaced tensions between the U.S. and China caught the market off guard in Friday's trading session, with the S&P 500 and Nasdaq falling over 2% on news that President Trump plans to impose an addi
US FDA adds boxed warning to J&J, Legend Biotech's cancer therapy
06:36pm, Friday, 10'th Oct 2025
The U.S. Food and Drug Administration on Friday approved labeling changes for Johnson & Johnson and its partner Legend Biotech's blood cancer therapy to include a boxed warning for a potentially fatal
Johnson & Johnson recommends shareholders reject “mini-tender” offer by Tutanota
04:20pm, Friday, 10'th Oct 2025
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that it has received notice of an unsolicited mini-tender offer by Tutanota LLC, a limited liability company establi
RTW Investments' Rod Wong: Expect more deals in biotech space
01:21pm, Friday, 10'th Oct 2025
Rod Wong, RTW Investments CIO & Managing Director, joins CNBC's 'Money Movers' to discuss J&J's reported interest in buying Protagonist Therapeutics, whether he expects more consolidation in the secto
Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know
01:10pm, Friday, 10'th Oct 2025
J&J gears up for Q3 results with solid gains from Darzalex, Tremfya and MedTech, even as Stelara faces fierce biosimilar pressure.
Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report
01:06pm, Friday, 10'th Oct 2025
Johnson & Johnson (NYSE:JNJ) is reportedly in discussions to acquire Protagonist Therapeutics (NASDAQ:PTGX).
Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports
11:25am, Friday, 10'th Oct 2025
Johnson & Johnson is in discussions to buy Protagonist Therapeutics , the Wall Street Journal reported on Friday, citing people familiar with the matter.
Johnson & Johnson in Talks to Buy Protagonist Therapeutics
11:13am, Friday, 10'th Oct 2025
The two companies are already codeveloping a treatment for ulcerative colitis.
Johnson & Johnson: A Safe Haven That's Quietly Becoming A Bit Overpriced
07:48am, Friday, 10'th Oct 2025
Johnson & Johnson is currently overvalued, with limited upside and mid-to-high single-digit long-term return potential amid ongoing sector risks. Despite solid recent earnings and raised guidance, JNJ
